Document:

EX-10.2

   

                     

  675 Massachusetts Avenue, 14th Floor

            Cambridge, MA 02139

  May 3, 2022

   

  Dr. David Melnick

   

  Dear David:

   

  	As was discussed with you, your employment with Spero Therapeutics, Inc. (the "Company")  is ending.  This letter is to summarize the terms of the separation package that the "Company is willing to offer you as a result of your separation from employment.  Please read this letter agreement (the “Letter Agreement”), which includes a general release, carefully.  If you are willing to agree to its terms, please sign in the space provided below and return it to me so that your separation benefits can begin.   

   

  1.Regardless of whether you choose to sign this Letter Agreement your employment with the Company terminates as of July 2, 2022 (“the Separation Date”).  If you are eligible for and properly elect to continue your medical and dental coverage under COBRA, the Company will contribute toward the cost of your COBRA premiums in the same amount as if you were actively employed (and any administrative fee), with such contribution ending on July 2, 2023. 

   

  2.After the Separation Date, unless otherwise provided in this Letter Agreement, you will not be entitled to receive any benefits paid by, or participate in any benefit programs offered by, the Company to its employees. You will receive, under separate cover, information concerning your right (if any) to continue your health insurance benefits after that date in accordance with COBRA.  

   

  3.In compliance with the promises made herein and in the event you sign this Letter Agreement and return it to me within time period set forth in the Letter Agreement and do not revoke your acceptance pursuant to Paragraph No. 9 below, the Company will also provide you with the following severance pay and benefits (the “Severance Benefits”):

   

  a.The Company will pay you severance as a continuation of payments in an amount equal to your current base salary for a nine (9) month period, which will equal $374,999.94 (three hundred seventy four thousand nine hundred ninety-nine dollars and ninety-four cents), less all customary and required taxes and employment-related deductions, in accordance with Company’s normal payroll practices  and commencing with the first reasonably practicable payroll cycle after the expiration of the revocation period set forth in Paragraph No. 9.

   

   

  

   

  b.The Company will pay you the gross amount of $100,273.96 (one hundred thousand two hundred seventy-three dollars and ninety-six cents) less lawful deductions, representing a pro-rated bonus, which will be paid to you when the Company pays the 2022 annual bonuses to its employees in the first quarter of 2023 but in any event no later than March 15, 2023.   You will not be entitled to receive any additional bonus monies.

   

  c.Provided that you are eligible for and properly elect to continue your medical coverage under COBRA, the Company will pay the full cost of your COBRA premium for such medical coverage, with such contribution ending on the earlier of (i) July 2, 2023; or (ii) the date on which you become eligible for coverage under the group medical plan of another employer.  Thereafter, you will be required to pay the full cost of any COBRA coverage for the remainder of the COBRA period. You agree to promptly notify the Company if you become eligible for coverage under the group medical plan of another employer during the time period that the Company is contributing towards the cost of your COBRA premiums.

   

  4.You understand and agree that you would not receive the Severance Benefits specified in Paragraph No. 3 above, except for your execution of this Letter Agreement and the fulfillment of the promises contained in this Letter Agreement.

   

  5.In consideration of the payments to be made by the Company to you as set forth in Paragraph No. 3 above and the promises contained in this Letter Agreement, you voluntarily and of your own freewill hereby release, forever discharge and hold harmless Spero Therapeutics, Inc., its parents, subsidiaries, divisions and affiliates, its present or former officers, directors, trustees, employees, agents, insurers, or successors or assigns from any and all claims, demands, rules or regulations, or any other causes of action of whatever nature, whether known or unknown, as of the date of your execution of this Letter Agreement, including, but not limited to any alleged violations of the National Labor Relations Act, as amended; Title VII of the Civil Rights Act of 1964, as amended; Sections 1981 through 1988 of Title 42 of the United States Code, as amended; the Age Discrimination in Employment Act of 1967, as amended; the Older Workers Benefit Protection Act; the Immigration Reform Control Act, as amended; the Employee Retirement Income Security Act of 1974, 29 U.S.C. § 1001, et seq. ("ERISA") (except for any vested benefits under any tax qualified benefit plan); the Occupational Safety and Health Act, as amended; the Civil Rights Act of 1866, 29 U.S.C. § 1981, et seq.; the Rehabilitation Act of 1973, 29 U.S.C. § 701, et seq.; the Americans With Disabilities Act of 1990, as amended; the Civil Rights Act of 1991; the Family and Medical Leave Act; the Equal Pay Act; the Fair Credit Reporting Act;  the Genetic Information Nondiscrimination Act (“GINA”); the Uniformed Services Employment and Reemployment Rights Act of 1994 (“USERRA”); the Worker Adjustment and Retraining Notification Act (WARN), 29 U.S.C. § 2101 et seq.; the Massachusetts Law Against Discrimination, G.L. c. 151B;  the Massachusetts Wage Payment Statute, G.L. c. 149, §§ 148, 148A, 148B, 148C, 149, 150, 150A-150C, 151, 152, 152A, et seq.; the Massachusetts Wage and Hour laws, G.L. c. 151§1A et seq.; the Massachusetts Privacy Statute, G.L. c. 214, § 1B; the Massachusetts Sexual Harassment Statute, G.L. c. 214 § 1C; the Massachusetts Civil Rights 

   

  

   

  Act, G.L. c. 12, § 11H; the Massachusetts Equal Rights Act, G.L. c. 93, § 102; the Massachusetts Equal Pay Act, G.L. c. 149, § 105A;  the Massachusetts Parental Leave Law, G.L. c. 149, § 105D; the Massachusetts Family and Medical Leave Law, G.L. c. 175M; or any other federal or state law, regulation, or ordinance; any public policy, contract, tort, or common law; or any allegation for costs, fees, or other expenses including attorneys’ fees incurred in these matters.  In addition, if any claim is not subject to release, to the extent permitted by law, you waive any right or ability to be a class or collective action representative or to otherwise participate in any putative or certified class, collective or multi-party action or proceeding based on such a claim in which the Company or any other releasee identified in this Letter Agreement is a party. 

   

  FOR THE AVOIDANCE OF DOUBT, THIS GENERAL RELEASE IS INTENDED TO RELEASE ANY AND ALL CLAIMS YOU MAY HAVE UNDER THE MASSACHUSETTS WAGE ACT AND IS INTENDED TO RESOLVE ANY AND ALL DISPUTES RELATED TO WAGES, COMMISSIONS, OR OTHER COMPENSATION.

   

  Notwithstanding the foregoing, you are not waiving any rights you may have to: (a) your own vested accrued employee benefits under the Company‘s health, welfare, or retirement benefit plans as of the Separation Date; (b) benefits and/or the right to seek benefits under applicable workers’ compensation and/or unemployment compensation statutes; (c) pursue claims which by law cannot be waived by signing this Letter Agreement; (d) enforce this Letter Agreement; and/or (e) challenge the validity of this Letter Agreement.

  
 SEQ CHAPTER \h \r 1 	6.	You agree not to disclose to anyone, either directly or indirectly, any information whatsoever regarding the existence or substance of this Letter Agreement, except your immediate family, attorneys, financial advisors, accountants, and tax preparation professionals, provided that they agree to keep such information strictly confidential.  This includes, but is not limited to, present or former employees of the Company and other members of the public.  You may also disclose this Letter Agreement to a state agency if required as part of an application for unemployment compensation benefits. You further agree not to make or publish any written or oral disparaging or defamatory statements regarding the Company, and its current and former employees, officers, directors and agents.  You understand and agree that your obligations under this paragraph are material terms of this Letter Agreement, and that the Company shall have the right, in addition to any other damages, to seek and obtain the return of the consideration paid hereunder (without impacting the validity or enforceability of the general release contained herein) in the event you breach any of your obligations under this paragraph. 

     

  7.	 You affirm that you have returned to the Company all keys, files, records (and copies thereof),  Company identification, Company vehicles and any other Company-owned property in your possession or control and have left intact all electronic Company documents, including but not limited to, those that you developed or helped develop during your employment.  Notwithstanding the foregoing, you are entitled to keep the Company equipment previously provided to you including computer hardware, printers, wireless handled devices, and cellular phones.  You understand that the Company would not provide you with the monies and benefits under this Letter Agreement but for your reaffirmation of 

   

  

   

  these obligations.  You further understand and agree that your obligations under this paragraph are material terms of this Letter Agreement, and that the Company shall have the right, in addition to any other damages, to seek and obtain the return of the consideration paid hereunder (without impacting the validity or enforceability of the general release contained herein) in the event you breach any of your obligations under this paragraph. 

  8.	You will be afforded a period of up to sixty (60) calendar days to consider the meaning and effect of this Letter Agreement.  You are advised to consult with an attorney, and you acknowledge that you have had the opportunity to do so.  You agree that any modifications, material or otherwise, do not restart or affect in any manner the original 60-day consideration period for the separation proposal made to you.   If you do not sign and return this Letter Agreement within the 60-day consideration period, the Company’s offer to provide you with the monies and/or other benefits set forth herein will expire.   

  9.	You may revoke this Letter Agreement for a period of seven (7) calendar days following the day you execute this Letter Agreement.  Any revocation within this period must be submitted, in writing, to Jamie Brady, Chief Human Resources Officer and state, “I hereby revoke my acceptance of the Letter Agreement.” The revocation must be personally delivered to Spero Therapeutics, Inc. 675 Massachusetts Avenue, 14th Floor, Cambridge, MA 02139, or both emailed (jbrady@sperotherapeutics.com) and mailed to Jamie Brady by first class mail and postmarked within seven (7) calendar days of execution of this Letter Agreement.  This Letter Agreement shall not become effective or enforceable until the revocation period has expired.  If the last day of the revocation period is a Saturday, Sunday, or legal holiday in Massachusetts, then the revocation period shall not expire until the next following day which is not a Saturday, Sunday, or legal holiday. 

  10.	This Letter Agreement, which will be construed under Massachusetts law, may not be modified, altered, or changed except upon express written consent of both parties wherein specific reference is made to this Letter Agreement.  You agree that any claims or causes of action which arise out of or relate in any way to this Letter Agreement shall be instituted and litigated only in, and you voluntarily submit to the jurisdiction over your person by, the courts of the Commonwealth of Massachusetts, or if appropriate, a federal court located in Massachusetts (which courts, for purposes of this Letter Agreement, are the only courts of competent jurisdiction).  You and the Company waive the right to a trial by jury with respect to any such claims or causes of action or other proceeding.

  11.	You acknowledge that you have received Attachment A to this Letter Agreement, which provides you with certain information regarding individuals selected and not selected for the Spring 2022 Restructuring Program (the “Program”).    

  12.	Nothing in this Letter Agreement prohibits or prevents you from filing a charge with or participating, testifying, or assisting in any investigation, hearing, or other proceeding before the U.S. Equal Employment Opportunity Commission, the National Labor Relations Board or a similar agency enforcing federal, state or local anti-discrimination laws.  However, to the maximum extent permitted by law, you agree that if such an administrative claim is made to such an anti-discrimination agency, you shall not be entitled to recover any 

   

  

   

  individual monetary relief or other individual remedies.  In addition, nothing in this Letter Agreement, including but not  limited to the release of claims nor the confidentiality and non-disparagement clauses, prohibits you from: (1) reporting possible violations of federal law or regulations, including any possible securities laws violations, to any governmental agency or entity, including but not limited to the U.S. Department of Justice, the U.S. Securities and Exchange Commission, the U.S. Congress, or any agency Inspector General; (2) making any other disclosures that are protected under the whistleblower provisions of federal law or regulations; or (3) otherwise fully participating in any federal whistleblower programs, including but not limited to any such programs managed by the U.S. Securities and Exchange Commission and/or the Occupational Safety and Health Administration. Moreover, nothing in this Letter Agreement prohibits or prevents you from receiving individual monetary awards or other individual relief by virtue of participating in such federal whistleblower programs. 

  13.	You affirm that you have been paid and have received all leave (paid or unpaid), compensation, wages, bonuses, commissions, severance pay, and/or benefits to which you may be entitled and that no other leave (paid or unpaid), compensation, wages, bonuses, commissions, severance pay, and/or benefits are due to you, except as provided in this Letter Agreement.  You further affirm that you have no known workplace injuries or occupational diseases and have been provided and/or have not been denied any leave requested under the Family and Medical Leave Act.  You also affirm that you have not been retaliated against for reporting any allegations of wrongdoing by the Company or its officers, including any allegations of corporate fraud.   In addition, you affirm that all decisions regarding your pay and benefits through the date of your execution of this Letter Agreement were not discriminatory based on age, disability, race, color, sex, religion, national origin or any other classification protected by law.  

  14.	You agree that neither this Letter Agreement, nor the furnishing of consideration for this Letter Agreement, shall be deemed or construed at any time for any purpose as an admission by the Company of any liability, wrongdoing, or unlawful conduct of any kind.       

  15.	You agree to cooperate with the Company in the investigation, defense or prosecution of any claims, actions or other matters now in existence or which may be brought in the future against or on behalf of the Company. Your cooperation in connection with such claims or actions shall include, but not be limited to, being reasonably available to meet with the Company’s counsel to prepare for discovery or any mediation, arbitration, trial, administrative hearing or other proceeding or to act as a witness when reasonably requested by the Company at mutually agreeable times and at locations mutually convenient to you and the Company.  Nothing herein shall require you to provide anything other than truthful information.

  16.	This Letter Agreement, which includes a general release, represents the complete agreement between you and the Company, and fully supersedes any prior agreements or understandings between the parties, other than any post-employment obligations you have under any agreement you have with the Company relating to 

   

  

   

  inventions, non-disclosure of confidential and proprietary information, non-solicitation and/or non-competition, which you agree to fully comply with to the fullest extent permitted by law.  You acknowledge that you have not relied on any representations, promises, or agreements of any kind made to you in connection with your decision to sign this Letter Agreement, except those set forth herein.

  17.	Should any provision of this Letter Agreement be declared illegal or unenforceable by any court of competent jurisdiction and cannot be modified to be enforceable consistent with the intent of the parties, excluding the general release language, such provision shall immediately become null and void, leaving the remainder of this Letter Agreement in full force and effect.  However, if the general release in Paragraph No. 5 is found to be invalid, you agree to execute a valid release of the claims that are the subject of this Letter Agreement and/or are referred to in the general release in Paragraph No. 5 above.

  18.	This Letter Agreement may be executed in counterparts, each of which when so executed shall be deemed an original, and the counterparts together shall constitute one and the same agreement. A copied, scanned, or faxed signature shall be treated the same as an original.

  [Remainder of Page Intentionally Left Blank]

   

   

   

  

   

   

  	The Company would like to extend its appreciation to you for your past service, and its sincere hope for success in your future endeavors.

  						Very truly yours,

   

  						/s/ Jamie Brady 

   

  						Jamie Brady

  					     Chief Human Resources Officer

  						 

  	 

   

  You have been advised in writing that you have a period of up to 60 calendar days to consider this Letter Agreement and to consult with an attorney prior to the execution of this Letter Agreement.

   

  	Having elected to execute this Letter Agreement, to fulfill the promises set forth herein, and to receive thereby the sums and benefits set forth in Paragraph No. 3 above, you freely and knowingly, and after due consideration, enter into this Letter Agreement by signing below intending to waive, settle, and release all claims (including, without limitation, any claims under the Age Discrimination in Employment Act of 1967) you have or might have against the Company, its subsidiaries, divisions and affiliates, its present or former officers, directors, trustees, employees, agents, insurers, or successors or assigns. 

   

  Date: 03 May 2022		/s/ David Melnick

  				                David Melnick

   

   

   

  

   

  ATTACHMENT A

   

  The following disclosure is provided by the Company in accordance with the Older Workers Benefit Protection Act (“OWBPA”), and applies to the Spring 2022 Restructuring Program (the “Program”).   The decisional unit for the Program included all employees of the Company.    

   

  Set forth below are the job titles, department and ages of all employees within the decisional unit who were selected or not selected for the Program.  Factors used in selecting individuals from the decisional unit for separation included performance, skill set, business need, tenure.  An “X” in the “Selected” column indicates that the individual is separating his/her employment with the Company as part of the Program (and is being offered severance in exchange for signing a separation agreement).     

   

  Job Title		Department		 	Age	      	Selected (x = selected)EX-10.3

  CONSULTING AGREEMENT

   

  This Consulting Agreement (the “Agreement”) is dated May 3, 2022 and is effective as of July 3, 2022 (the “Effective Date”) by and between Spero Therapeutics, Inc., with offices located at 675 Massachusetts Avenue, 14th Floor, Cambridge, MA 02139, together with its subsidiaries and affiliates (collectively, “Spero”) and Cristina Larkin (“Consultant”). Spero and Consultant shall be referred to individually as a “Party” and together as the “Parties”. 

   

  1.Description of Services. 

   

  A.Consultant is hereby retained by Spero to perform the following consulting services (the “Services”): to advise Spero on Commercial, Medical Affairs, Business Development and general operational and strategic matters.  

   

  B.Consultant shall perform the Services personally, without resort to any delegate or assignee without the prior written permission of Spero, and in conformity with generally accepted professional standards.

   

  2.Representations, Warranties, and Covenants. Consultant represents and warrants:

   

  A.Consultant has no authority (and shall not hold himself/herself out as having authority) to bind Spero without prior written authorization.

   

  B.Consultant (i) has disclosed to Spero any potential conflict of interest in connection with the provision of Services hereunder; (ii) is not under any existing obligation that is inconsistent with this Agreement or would restrict or conflict with the performance of Consultant’s obligations hereunder; and (iii) shall promptly disclose to Spero any such conflict that may arise during the term of this Agreement. In the event that any conflict of interest arises, Spero, as it deems necessary, shall have the right to terminate this Agreement and/or require Consultant to refrain from performing any portion of the Services related to the conflict of interest. Nothing in this Section shall be construed so as to relieve Consultant of any of his/her obligations under this Agreement.

   

  C.That the terms of this Agreement do not violate the terms of any other contractual or legal obligations Consultant may have or any policies of any institution with which Consultant is associated or employed.

   

  D.Consultant is not affiliated with the U.S. Department of Veterans Affairs, the National Institutes of Health or any other federal, state, or local government institution, or, if Consultant is so affiliated, Consultant has provided a signed acknowledgement form of an authorized official from said institution before executing this Agreement.

   

  E.Consultant will comply with all applicable laws with respect to the Services performed under this Agreement including without limitation, and as applicable, the Health Insurance Portability and Accountability Act of 1996, the Foreign Corrupt Practices Act of 1977, and the OECD Convention on Combatting Bribery of Foreign Public Officials in International Business Transactions; any amendments to and regulations promulgated under all of the foregoing laws; and all comparable state and local laws applicable to the Services.

   

  F.Consultant is not debarred under the U.S. Generic Drug Enforcement Act of 1992, 21 U.S.C. Sections 335a (a) and (b), as amended.  Consultant also represents and warrants that Consultant is not sanctioned by a Federal Health Care Program (as defined in 42 U.S.C. Section 1320 a-7b(f)), including, but not limited to, the federal Medicare or a state Medicaid program, or debarred, suspended, or excluded from any Federal agency or program.  Consultant agrees to notify Spero immediately in the event that Consultant becomes debarred, suspended, excluded, or otherwise sanctioned, or receives notice of such action.  

  Page 1 of  NUMPAGES  3

   

  

   

  3.Compensation and Payment. 

   

  A.In consideration for Consultant’s performance of the Services, Spero shall pay Consultant three hundred dollars ($300) per hour.  

   

  B.The equity that the Consultant received from Spero under Spero’s 2017 Stock Incentive Plan (the “Equity Plan”) shall continue to vest in accordance with the terms of the Equity Plan during the term of this Agreement. Consultant may exercise any vested options or restricted stock units during the term of this Agreement and for ninety (90) days thereafter in accordance with the terms of the Equity Plan and the terms of any Stock Option Grant Notice or Stock Option Agreement or Restricted Stock Unit Agreement issued under the Equity Plan.   

   

  C.Spero shall reimburse Consultant for authorized, documented and reasonable travel and other direct out-of-pocket expenses incurred by Consultant during the performance of the Services under this Agreement. 

   

  D.Consultant shall submit invoices that reference the purchase order number issued by Spero to invoices@sperotherapeutics.coupahost.com. Spero shall make payments to Consultant within thirty (30) days of receipt of invoices. 

   

  4.Confidentiality; Restrictions on Publications.

   

  A.In the course of performing the Services, Consultant may be given, or have access to, confidential and proprietary information of Spero or the Spero’s business partners, including, but not limited to, information relating to pricing, marketing strategies and tactics, products, processes, methods, techniques, formulas, compositions, compounds, financial data, personal data, computer programs, customer and supplier lists, contacts or knowledge of customers or prospective customers of Spero, clinical research and development, and/or the approval, administration, use or experience of any or all of Spero or Spero’s business partners’ products (whether approved or in development), all of which information is considered confidential by Spero and of irreplaceable value (collectively, “Confidential Information”). 

   

  B.Consultant hereby agrees to use such Confidential Information, whether prepared by Consultant or otherwise coming into Consultant’s possession, solely to render the Services pursuant to this Agreement. Consultant further agrees that all files, documents, records and similar items relating to any Confidential Information, whether prepared by Consultant or otherwise coming into Consultant’s possession, shall remain the Confidential Information of Spero. During the term of this Agreement and for a period of ten (10) years from the date of the Agreement’s termination or expiration, Consultant shall not use or disclose to any third party any Confidential Information without Spero’s prior written consent. 

   

  C.At any time, upon request by Spero, or immediately on the expiration or earlier termination of this Agreement, whichever event occurs first, Consultant shall return to Spero or destroy (and certify such destruction in writing) all originals and copies of Confidential Information, including, but not limited to, any files, notes, memoranda, documents, records, analyses, any and all excerpts or other similar items, whether in written, electronic or other format. 

   

  D.Consultant shall not publish, nor submit for publication, any document describing, resulting from, or otherwise related to the performance of the Services without obtaining Spero’s prior written consent.

   

  E.Consultant shall keep confidential the existence of this Agreement and the terms of this Agreement. Consultant agrees not to identify Spero in any of Consultant’s marketing materials, lists of clients or for any other purpose whatsoever without Spero’s prior written consent.

   

  Page 2 of  NUMPAGES  3

   

  

  F.Consultant’s obligations under this Section 4 shall not apply to any Confidential Information that (i) is or becomes known to the general public under circumstances involving no breach by Consultant or others of the terms of this Section 4, (ii) is approved for release by written authorization of an officer of Spero, (iii) at the time of disclosure is, or thereafter becomes, available to the Consultant from a third party source on a non-confidential basis, provided that such third party is not and was not prohibited from disclosing such Confidential Information to Consultant by any legal, fiduciary or contractual obligation, (iv) was known by or in the possession of the Consultant, as established by documentary evidence, prior to being disclosed by or on behalf of Spero in connection with the Services, or (v) was or is independently developed by Consultant, as established by documentary evidence, without reference to or use of, in whole or in part, any Confidential Information. 

   

  G.If the Consultant is required by order, subpoena, summons, law or regulation to disclose any Confidential Information, the Consultant shall (i) notify Spero as promptly as practicable in writing of such requirement so that Spero may seek a protective order or other appropriate remedy, (ii) furnish only that portion of the Confidential Information which the Consultant is legally required to disclose, in accordance with advice of counsel, and (iii) exercise all reasonable efforts to obtain reliable assurances that confidential treatment will be accorded to such Confidential Information. The Consultant shall, at the sole expense of Spero, cooperate with Spero in its efforts to obtain a protective order or reliable assurance that only the designated portion of the Confidential Information shall be disclosed. 

   

  H.Consultant shall not disclose to Spero any information which is confidential or proprietary to a third party without first obtaining the written consent of both such third party and Spero.

   

  I.Notwithstanding the foregoing, obligations of confidentiality and non-use with respect to any Confidential Information identified as a trade secret by Spero shall remain in place for so long as the applicable Confidential Information retains its status as a trade secret under applicable law.

   

  5.Intellectual Property. All inventions, discoveries, information, data, concepts, reports, innovations or other intellectual property (collectively, “Intellectual Property”) that may arise from Consultant’s performance of the Services shall be promptly disclosed to Spero, and title thereto shall immediately vest in Spero or such designated member of Spero. Consultant agrees that all information and written materials prepared in the performance of the Services to be “works for hire” and copyright therein shall immediately vest in Spero or such designated member of Spero. During the term of this Agreement and thereafter, Consultant agrees to cooperate fully with, and assist Spero in filing, prosecuting patent, trademark and/or copyright applications and otherwise protecting Spero’s rights to the Intellectual Property described in this Section 5. In this regard, Consultant agrees to execute any assignments and other documents as Spero deems necessary to protect its rights to any such Intellectual Property. 

   

  6.Independent Contractor. Spero and Consultant agree that Consultant’s status under this Agreement shall be that of an independent contractor and that Consultant is not an agent or employee of Spero. Consultant acknowledges and agrees that Consultant is not entitled to any benefits, coverages, or privileges, including, without limitation, social security, unemployment, medical or pension payments, paid time off, tax withholding or other benefits routinely provided to employees. 

   

  7.Term and Termination.

   

  A.The term of this Agreement shall commence on the Effective Date and subject to earlier termination in accordance with this Agreement, shall continue until May 3, 2023, when it will automatically expire. 

   

  B.Either Party may terminate this Agreement at any time upon fifteen (15) days’ prior written notice to the other Party. During such notice period, Consultant shall continue to perform the Services unless otherwise requested by Spero.

  Page 3 of  NUMPAGES  3

   

  

   

  C.Either Party may terminate this Agreement immediately upon written notice to the other Party if said other Party commits a material breach of any term hereof which is not cured to the satisfaction of the non-breaching Party within fifteen (15) days of written notice of said breach.

   

  D.The provisions of Sections 2, 4, 5, 8, 9, 10, 11, and 15 shall survive any termination or expiration of this Agreement.

   

  8.Receipt of Reportable Information by Consultant. 

   

  A.To the extent any Services performed by Consultant pursuant to this Agreement result in Consultant’s collection, receipt or other form of knowledge of any information about Spero drug products (collectively, “Product(s)”), from any source, in any form, relating to an Adverse Drug Experience (“Reportable Information”), Consultant represents and warrants that he/she shall cooperate with Spero as set forth in this provision. 

   

  B.For purposes of this Section 8, the term “Adverse Event” shall mean any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment.

   

  C.An Adverse Event can therefore be any unfavorable and unintended sign (including abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.

   

  D.A serious Adverse Event or reaction is any untoward medical occurrence that at any dose results in death, is life-threatening (an event in which the patient was at risk of death at the time of the event; it does not refer to an event which hypothetically might have caused death if it were more severe), requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, or is a congenital anomaly/birth defect.

   

  E.Consultant shall preserve the original record of such Reportable Information and within one (1) business day on which such Reportable Information was received or otherwise became known to Consultant, Consultant shall submit a copy of such records and information to Spero, including (i) the identification and contact information for both the person receiving the Reportable Information and the person submitting such Reportable Information to Spero; (ii) the date on which Consultant received the Reportable Information; and (iii) the identification of the Product(s) in question and all known facts regarding the event underlying the Reportable Information, including identifying the subject thereof. 

   

  9.Injunctive Relief. Without limiting Spero’s remedies in any way, Consultant agrees that Spero shall be entitled to injunctive relief to prevent any actual or threatened breach or continuing breaches by Consultant of this Agreement since such actual or threatened breach would cause irreparable harm to Spero that could not reasonably or adequately be compensated by damages in an action of law.

   

  10.Liability and Indemnification. Spero shall not be liable for any loss, injury or damage incurred by Consultant or by a third party as a result of Consultant’s performance of the Services, including any loss, injury or damage resulting from the negligent or willful act or omission by Consultant. Consultant shall indemnify and hold Spero harmless from any liability, loss, cost and expense (including attorneys’ fees and costs) incurred by Spero as a result of Consultant’s negligent acts or omissions or breach of this Agreement.

   

  11.Compliance with Law. 

   

  A.Consultant acknowledges that Spero from time to time may have agreements with government 

  Page 4 of  NUMPAGES  3

   

  

  agencies that impose obligations or restrictions on Spero regarding inventions made during the course of work under such agreements or regarding the confidential nature of such work. Consultant agrees to be bound by all such obligations and restrictions known to Consultant and to take all action necessary to discharge the obligations of Spero under such agreements. By signing this Agreement, Consultant consents to Spero:

   

  i.Collecting, processing and storing Consultant’s information, including his/ her contact details, and the payments and transfers of value made to the Consultant under this Agreement.

   

  ii.Making public disclosures of such information in accordance with the applicable laws, regulations or codes of conduct. Such disclosures may be made using any media (paper or electronic), web-site or platform, including an industry association’s electronic platform. The information to be published will clearly identify the Consultant and the types of transfers of value he or she received from Spero.

   

  iii.Disclosing such information to pharmaceutical industry associations and/or competent authorities for compliance with applicable laws, regulations or codes of conduct.

   

  12.Privacy. Consultant shall comply with the provisions of the Privacy and Security Addendum attached hereto and incorporated by reference as Exhibit A.

   

  13.Notice and Notification. Any notice, report or other written communication required or permitted to be made or given hereunder may be made or given by either Party to the other by personal in hand delivery; by first class mail, postage prepaid; by electronic mail; or by air courier to the mailing address set forth above or to such other address as either Party shall designate by written notice, similarly given, to the other Party.  Notices to Spero will be marked “Attention: Legal”.    Notices or written communications shall be deemed to have been sufficiently made or given (i) if by personal in hand delivery, when performed; (ii) if by electronic mail, when promptly confirmed by reply of the receiving party; (iii) if mailed, three (3) days after being deposited in the mail, postage prepaid; or (iv) if by air courier, one (1) day after delivery to the air courier company.

   

  14.Assignment. Neither Party may assign all or any part of this Agreement without the prior written consent of the other Party; provided, however, that Spero may assign this Agreement to a corporate affiliate or to a successor to all or substantially all of its business without obtaining prior written consent from Consultant.

   

  15.Governing Law. This Agreement shall be governed by and construed in accordance with the laws of the Commonwealth of Massachusetts without regard to its conflict of laws provisions. Each Party agrees to submit to the exclusive jurisdiction of the courts of Boston, MA over any claim or matter arising under or in connection with this Agreement. 

   

  16.Amendments. This Agreement may not be amended except in writing signed by duly authorized representatives of both Parties.

   

  17.Severability. If any one or more of the provisions of this Agreement shall, for any reason, be held invalid, illegal or unenforceable in any respect, it shall not affect any other term or provision of this Agreement. If any provision in this Agreement shall be held to be excessively broad, it shall be construed by limiting it so as to be enforceable to the extent compatible with applicable law.

   

  Page 5 of  NUMPAGES  3

   

  

  18.Entire Agreement. This Agreement, including Exhibit A, any subsequent exhibits, and any exhibits attached hereto, sets forth the entire agreement and understanding of the Parties with respect to the subject matter described herein and supersedes all prior written or oral agreements relating to said subject matter. In the event of any inconsistency between the provisions of this Agreement and Exhibit A, the provisions of this Agreement shall govern. No waiver of any term, provision or condition of this Agreement, whether by conduct or otherwise in any one or more instances shall be deemed to be or construed as further or continuing waiver of any such term, provision or condition, or of any other term, provision or condition. The invalidity or unenforceability of any term or provision of the Parties with respect to the subject matter of this Agreement shall not affect the validity or enforceability of any other term or provision of this Agreement. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original and all of which together shall constitute one and the same instrument.

   

  [Remainder of Page Intentionally Left Blank]

   

  Page 6 of  NUMPAGES  3

   

  

  The foregoing is acknowledged, understood and agreed to effective as of the Effective Date as evidenced by execution of an authorized representative of each Party in the spaces below.

   

  		
	 
Spero Therapeutics, Inc.
 
 
 
By: /s/ Tamara Joseph
 
Name:  Tamara Joseph
 
Title:   Chief Legal Officer
 
 
	 
Cristina Larkin
 
 
 
By: /s/ Cristina Larkin
 
 

   

   

   

   

   

   

   

   

   

   

   

   

   

   

  	 

  	 

  Page 7 of  NUMPAGES  3

   

  

   

  Exhibit A

   

  Privacy and Security Addendum

   

  1.Definitions.  

   

  A.Capitalized terms not defined in this Privacy and Security Addendum (“Addendum”) herein shall have the meaning ascribed to them in the Agreement. 

   

  B.“Personal Information” means any information that is processed under this Agreement that identifies or that, together or in connection with other information, can be uniquely linked to an individual. 

   

  2.Consultant Obligations.

   

  A.Consultant represents, warrants and covenants his/her collection, access, use, storage, disposal and disclosure of any Personal Information does and will comply with all applicable privacy and data protection laws. 

   

  B.Consultant shall process Personal Information in accordance with Spero’s written instructions and only as necessary to carry out its obligations pursuant to this Agreement, or as required by applicable law.

   

  C.Consultant shall take reasonable and appropriate measures to protect Personal Information from loss, misuse and unauthorized access, disclosure, alteration and destruction.

   

  D.In the event that Consultant discloses Personal Information to a third party, Consultant shall enter into an agreement with such third parties that includes terms consistent with the terms of this Addendum.

   

  E.Consultant will notify Spero as soon as practicable, but no later than twenty-four (24) hours after Consultant becomes aware that the security, confidentiality or integrity of Personal Information has been compromised and Consultant will fully cooperate with Spero to comply with any obligations that arise from the unauthorized access of the Personal Information. 

   

  F.In the event that Consultant receives an access request, inquiry or complaint from the data subject, Consultant shall not respond without, and then only in accordance with, the prior written approval of Spero, unless required by applicable law. Consultant shall promptly carry out any request from Spero to amend, transfer, or delete, or to provide Spero with a copy of the Personal Information, in whole or in part.

   

  G.When Personal Information collected by Consultant under the terms of this Agreement is no longer necessary for the performance of Services under this Agreement, Consultant shall securely destroy or, at Spero’s written request, return to Spero or its designee, all Personal Information in Consultant’s possession, custody or control, unless prohibited by applicable law.

   

  H.Consultant shall notify Spero if it determines that it can no longer meet its obligations under this Addendum and, at Spero’s direction, cease processing Personal Information.

   

  I.Consultant shall comply with the terms of this Addendum for as long as it is in possession of Personal Information.

  	Page 8 of  NUMPAGES  9

   

  

   

   

  3.Cross-Border Transfers of Personal Information. Personal Information Consultant provides to Spero, its affiliates or vendors acting on their behalf may be transferred to the United States and other countries which may not provide the same level of protection of Personal Information as the one in which Consultant resides. Spero will handle Personal Information in accordance with Spero policies and applicable law regardless of where Personal Information is processed. 

   

  4.Consultant Consent and Privacy Information.

   

  A.Consultant hereby consents that Spero and vendors acting on its behalf in order to assist with the Services provided hereunder may collect, use, store and disclose Consultant’s Personal Information provided or collected under this Agreement. Consultant may withdraw consent at any time.

   

  B.Consultant can exercise his/her right to request access to Personal Information himself/herself by contacting Spero Edwin Sopp of Spero at esopp@sperotherapeutics.com.

   

  C.Questions or complaints regarding the processing of Personal Information can be sent to Edwin Sopp at esopp@sperotherapetuics.com. Complaints can also be made to the competent supervisory authority.

   

  D.Personal Information collected and processed for purposes of this Agreement shall be processed and stored by Spero for as long as is necessary to fulfill the purposes of this Agreement.

   

   

   

   

   

  Page 9 of  NUMPAGES  9

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00347-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00347-of-00352.parquet"}]]